Efferon is a biotech company developing hemoadsorption devices designed to remove endotoxins and inflammatory mediators from the bloodstream for the treatment of sepsis, septic shock and other inflammation-related conditions.
Biotech
company Efferon has raised €2.5 million in a seed funding round led by private
investors from the DACH region to support the European commercial expansion of
Efferon LPS, its hemoadsorption device approved for the treatment of sepsis and
septic shock.
With new funding, NEX Health Intelligence plans to expand its AI-powered infection intelligence platform across hospitals in the…
On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for…
Paris and San Francisco-based Lauxera Capital Partners has closed a €520M healthtech growth fund to help commercial-stage…
SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa…
The operation raised €60 million, a third of which came from Sanofi, which will hold 13.9% of the company's shares.
London-based NEX Health Intelligence has raised €1M in pre-seed funding to help hospitals predict where drug-resistant infections…
